Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | HTR2C | P28335 | 5/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 3/20 | 0.41 |
| ▸ | S100A4 | P26447 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.38 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | AADAT | Q8N5Z0 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PPOX | P50336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30666697 | 1.00 | METAP1 (0.53) | METAP1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL7847032 | 0.85 | METAP1 (0.43) | METAP1HTR2AHTR2CHTR2BHTR1A | |
| SCHEMBL6190707 | 0.82 | TDP2 (0.51) | METAP1NOTUM | |
| SCHEMBL6205730 | 0.82 | MAOA (0.48) | METAP1CES1 | |
| SCHEMBL11566215 | 0.82 | DRD2 (0.43) | METAP1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL8555030 | 0.79 | METAP1 (0.54) | METAP1S100A4CES1SRD5A1SRD5A2 | |
| SCHEMBL7590593 | 0.79 | METAP1 (0.54) | METAP1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL29404958 | 0.78 | METAP1 (0.56) | METAP1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL30666881 | 0.78 | ACHE (0.46) | METAP1SIGMAR1HTR2AHTR2CHTR2B | |
| SCHEMBL11563001 | 0.78 | METAP1 (0.53) | METAP1SIGMAR1HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | SERVIER LAB (FR) | 2026-01-01 | — | — | US | disclosed |
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | VERNALIS (R&D) LTD (GB) | 2024-05-09 | — | — | US | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| EP-4265613-A1 | BENZENE RING COMPOUND AND USE THEREOF | Nanjing Shijiang Medicine Technology Co., Ltd (CN) | 2023-10-25 | — | — | EP | disclosed |
| CN-116940552-A | Spirocyclic hexane derivatives, pharmaceutical compositions containing them and their use as anti-apoptotic inhibitors | 法国施维雅药厂 | 2023-10-24 | — | — | CN | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| CN-102884044-A | Derivatives of aminoindanes, their preparation and their application in therapeutics | SANOFI SA | 2013-01-16 | — | — | CN | disclosed |
| EP-2542524-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-01-09 | — | — | EP | disclosed |
| US-6090833-A | EATING DISORDERS; ANTIDIABETIC AGENT | AVENTIS PHARMA DEUTSCHAND GMBH (DE) | 2000-07-18 | — | — | US | disclosed |
| WO-2000018749-A1 | INDENO-, NAPHTO- AND BENZOCYCLOHEPTA DIHYDROTHIAZOLE DERIVATIVES, THE PRODUCTION THEREOF AND THEIR USE AS ANORECTIC MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
| WO-1999042455-A1 | ANTIVIRAL AGENTS | TULARIK INC. (US) | 1999-08-26 | — | — | WO | disclosed |
| EP-0662971-B1 | 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE DERIVATIVES, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM | RHONE POULENC RORER SA (FR) | 1998-05-13 | — | — | EP | disclosed |
| US-5677306-A | ANTAGONIZING ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID RECEPTOR, USEFUL FOR TREATING ALL ISCHEMIAS | RHONE-POULENC RORER S.A. (FR) | 1997-10-14 | — | — | US | disclosed |
| EP-0662971-A1 | DERIVATIVES OF 5H,10H-IMIDAZO 1,2-a]INDENO 1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM | Aventis Pharma S.A. (FR) | 1995-07-19 | — | — | EP | disclosed |
| WO-1994007893-A1 | DERIVATIVES OF 5H,10H-IMIDAZO[1,2-a]INDENO[1,2-e]PYRAZINE-4-ONE, PREPARATION THEREOF AND MEDICAMENTS CONTAINING THEM | RHONE-POULENC RORER S.A. (FR) | 1994-04-14 | — | — | WO | disclosed |
| US-4174397-A | TREATMENT OF OBESITY AND LIPID METABOLISM DISORDERS | HOECHST AKTIENGESELLSCHAFT (DE) | 1979-11-13 | — | — | US | disclosed |
| US-3932430-A | Substituted indeno, naphtho and cyclohepta pyrazoles | SANDOZ, INC. (US) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150293-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BAX, BCL2A1 | METAP1 4494/4885SIGMAR1 685/4885HTR2A 2445/4885 |
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | ANXA2, ANXA3, ADM2 | METAP1 843/4885SIGMAR1 777/4885HTR2A 464/4885 |
| US-20260001846-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | BCL2, BCL2A1, BAX | METAP1 3656/4885SIGMAR1 426/4885HTR2A 3518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.